Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Pseudoangiosarcoma and cutaneo...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Pseudoangiosarcoma and cutaneous collagenous vasculopathy in a patient on a Bruton’s tyrosine kinase inhibitor

Pseudoangiosarcoma and cutaneous collagenous vasculopathy in a patient on a Bruton’s tyrosine kinase inhibitor

Bibliographic Details
Main Authors: Alison H. Kucharik, MD, Nina B. Curkovic, BS, Julio C. Chavez, MD, Kenneth Y. Tsai, MD, PhD, Andrew S. Brohl, MD, James M. Grichnik, MD, PhD
Format: Article
Language:English
Published: Elsevier 2024-09-01
Series:JAAD Case Reports
Subjects:
angiosarcoma
Bruton’s tyrosine kinase inhibitor
BTKi
CCV
cutaneous collagenous vasculopathy
Online Access:http://www.sciencedirect.com/science/article/pii/S2352512624002352
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

http://www.sciencedirect.com/science/article/pii/S2352512624002352

Similar Items

  • Targeting Bruton’s tyrosine kinase (BTK) as a signaling pathway in immune-mediated diseases: from molecular mechanisms to leading treatments
    by: Gita Manzari Tavakoli, et al.
    Published: (2024-08-01)
  • Bruton’s tyrosine kinase inhibitors in the treatment of primary central nervous system lymphoma: A mini-review
    by: Jing Shen, et al.
    Published: (2022-11-01)
  • The Possible Role of Bruton Tyrosine Kinase Inhibitors in the Treatment of COVID-19: A Review
    by: Mitra Rezaei, MD, et al.
    Published: (2022-01-01)
  • Bruton’s tyrosine kinase inhibitor associated localized extremity edema and erythema
    by: Shannon Meledathu, BS, et al.
    Published: (2024-12-01)
  • Bruton’s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials
    by: Dariusz Rozkiewicz, et al.
    Published: (2023-03-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs